Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better.

Abstract

Due to relatively high nonrelapse mortality (NRM), allogeneic hematopoietic stem cell transplantation (allo-HSCT) in non-Hodgkin's lymphoma (NHL) remains the ultimate line of treatment but the only curable approach in a setting of relapse/refractory disease. Here, we conducted a retrospective, multicenter, registry-based analysis on patients who underwent allo-HSCT for NHL in Switzerland, over 30-year (1985-2020) period. The study included 301 allo-HSCTs performed for NHL patients in three University Hospitals of Switzerland (Zurich, Basel and Geneva) 09/1985 to 05/2020. We assessed in univariate and multivariable analysis the impact on survivals (overall survival [OS], relapse free survival [RFS], relapse incidence [RI], and non-treatment related mortality [NRM]). The maximum follow-up was 25 years with median follow-up for alive patients of 61 months. The median age at allo-HSCT was 51 years. Three- and -year OS was - 59.5% and 55.4%; 3- and 5-year PFS was 50% and 44%; 3- and 5-year NRM was 21.7% and 23.6%. RI at 3 and 5 years was 27.4% and 34.9%. In conclusion, our analysis of the entire Swiss experience of allo-HSCT in patients with NHL shows promising 5- and possibly 10-year OS and relatively acceptable NRM rates for such population, the majority being not in complete remission (CR) at the time of transplantation.

• Authors: Ekaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, Paraskevi Stakia, Alix Stern, Michael Medinger, Stavroula Masouridi-Levrat, Carole Dantin, Urs Schanz, Helen Baldomero, Jakob Passweg, Gayathri Nair, Alicia Rovo, Yves Chalandon
• Journal: EJHaem (EJHaem) Vol. 4 Issue 1 Pg. 258-261 (Feb 2023) ISSN: 2688-6146 [Electronic] United States
• PMID: 36819159 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.